Overview
This test assists in the diagnosis of autoimmune myasthenia gravis (MG) with acetylcholine receptor (AChR) antibodies. This is the first-line test in our MG antibody panel.
| Test Code: | AChR RIPA |
| Methodology: | In-house radioimmunoprecipitation |
| Validation: | Laboratory developed test (LDT) |
Requirements
| Specimen type | Serum |
| Minimum volume | 0.5 mL |
| Preferred volume | 3 mL |
| Rejection criteria | Grossly hemolytic, lipemic, or icteric. If the sample arrives at room temperature. |
Specimen
| Specimen collection | No patient preparation is required for sample collection. |
| Specimen handling | Centrifuge SST tubes at 1800 - 2200 x g for 10-15 minutes |
| specimen stability | Serum samples may be stored: |
Performance
| Testing frequency | Once per week (2-day procedure) |
| Turnaround time | 2-8 days |
| Reference range | Negative: 0.0 – 0.2 nmol/L |
Additional Information
- This test was developed and its performance determined by Neurocode USA Inc. It has not been cleared or approved by the Food and Drug Administration.
- Please indicate if patients are on immunomodulating treatments as these may interfere with testing.
- Causal antibodies cannot be identified in about 10% of MG cases. Therefore, a positive result is specific for the diagnosis of AChR ab myasthenia gravis (MG), but a negative result does not rule out an MG diagnosis.
Order Acetylcholine Receptor Antibodies by Radioimmunoprecipitation (AChR RIPA) Test
Reach out to our specialists today to start the ordering process.
Order Test